Navigation Links
Princess Margaret breast cancer research finds new drug target companion prognostic test for hormone therapy resistance
Date:4/1/2013

(TORONTO, Canada April 1, 2013) A team of international cancer researchers led by Dr. Mathieu Lupien at the Princess Margaret Cancer Centre, University Health Network, has identified the signalling pathway that is over-activated in estrogen receptor (ER)-positive breast cancer cells that are resistant to hormone therapies such as tamoxifen, aromatase inhibitors or fulvestrant.

Resistance to hormone therapy is reported in almost half of ER-positive breast cancer patients and no cure is currently available. The fact that the pathway, called Notch, is a drug target creates hope for a new therapy.

The findings, published online today in PNAS, the Proceedings of the National Academy of Sciences of the United States of America, "provide a new therapeutic target against hormone therapy-resistant breast cancers and a companion test to identify tumours that would become resistant" says Dr. Lupien, a scientist at the Ontario Cancer Institute, the research arm of the cancer centre, and an Assistant Professor in the Department of Medial Biophysics, University of Toronto. He specializes in epigenetics of hormone-dependent cancers the study of non-genetic determinants of cellular identity that can also be altered to initiate or modify disease.

"In studying the epigenetics of hormone therapy resistance, we discovered that breast cancer cells behave like a chameleon. Indeed, as the chameleon changes its skin colour to camouflage itself and evade predators," says Dr. Lupien, "breast cancer cells change the appearance of their DNA through epigenetics to evade, in this case, hormone therapy." In so doing, hormone therapy-resistant breast cancer cells highlight regions of their DNA related to the Notch pathway.

At the molecular level, the research team characterized the epigenetic appearances of the DNA of drug-resistant and drug-responsive breast cancer cells. The team discovered that the Notch signaling pathway plays the predominant role in drug-resistant breast cancer cells even if cells remain positive for ER.

"This is a highly promising discovery that could rapidly translate in the clinic. Drugs against the Notch pathway are available." says Dr. Lupien. The key will be to test the efficacy of these drugs against hormone therapy resistance in breast cancer.


'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.ca
416-946-2846
University Health Network
Source:Eurekalert

Related medicine news :

1. HRH Crown Princess Mary of Denmark announced as patron of Australian and Danish twin registries
2. Blue Deer Center in Margaretville, New York, Welcomes Theodore Finkle as New Center Manager
3. Plant Spirit Medicine Healer Training Begins March 2013 at Blue Deer Center in Margaretville, NY
4. ASH honors Margaret A. Goodell, Ph.D., with 2012 William Dameshek Prize
5. More Evidence Shows Hormone Therapy May Increase Breast Cancer Risk
6. When Breast Cancer Spreads to Lungs, Surgery May Increase Survival
7. Estrogen plus progestin use linked with increased breast cancer incidence and mortality
8. Author of new breast cancer study comments on its findings of increased risk
9. University of Maryland breast cancer research pioneer Dr. Angela Brodie named AACR Academy Fellow
10. Associated Plastic Surgeons & Consultants Reports that Insurance Denied Payment for Bilateral Breast Reconstruction Following Mastectomy
11. Newly Release Video Reveals Technical aspects of Advanced Breast Augmentation Surgery The Cold-Subfascial Breast Augmentation TM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... MD (PRWEB) , ... February 08, 2016 , ... ... is excited to share this important news! AHCC and the Home Health and ... Coding Clinic, CMS' designee for official ICD coding guidance and clarifications, to address ...
(Date:2/8/2016)... ... 2016 , ... The schedule is now online for the largest ... which is being held May 25-29 at the Loews Chicago O’Hare Hotel, continues to ... causes of chronic illness in children. , Very recent articles have cited 1 child ...
(Date:2/7/2016)... ... 2016 , ... HealthSmart Holdings, Inc. announced today the launch ... and information to lower the costs, and increase the impact of their healthcare ... healthcare benefits by as much as 22%:, + Price and quality transparency, ...
(Date:2/6/2016)... ... ... With the FCPX LUT: Summer pack from Pixel Film Studios, ... is a Lookup Table that contains a mathematical formula for modifying an image. The ... manipulating each pixel, LUT's can change each color range differently, it gives the user ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... PALO ALTO, Calif. , Feb. 8, 2016 ... chemical manufacturing, and Kodiak Sciences Inc., a biopharmaceutical company ... retinal disease, announced today agreements for the clinical supply ... manufacture material at multiple sites, including Slough (UK), Visp ... --> Retinal diseases, such as age-related ...
(Date:2/8/2016)... N.C. , Feb. 8, 2016  Avista Pharma ... Eric Setzer as Chief Financial Officer (CFO). Mr. ... twenty years of experience in various roles within growing ... Pharma, he served as the Executive Director of Finance ... in Raleigh, NC . Previously, Mr. ...
(Date:2/8/2016)... Vestagen Technical Textiles, Inc., a medical technology ... and other demanding applications, today announced it has named ... Dale Pfost , PhD, who was serving as ... joining Vestagen,s Board of Directors. ® , ... technologies that combines fluid repellent, antimicrobial and breathability properties. ...
Breaking Medicine Technology: